Outcomes of unselected recipients of sirolimus-eluting stents: The cypher® stent U.S. post-marketing surveillance registry

Journal of Invasive Cardiology

Volumn 22, Issue 2, 2010, Pages 48-55

  Bezerra, Hiram ^a   Perin, Emerson ^b   Berger, Peter ^c   Block, Peter ^d   Ramee, Stephen ^e   Katz, Stanley ^f   Kellet, Mirle ^g   Dippel, Eric ^h   Schaer, Gary ⁱ   Britto, Suzanne ^j   Cohen, Sidney ^j   Costa, Marco ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b TEXAS HEART INSTITUTE   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e OCHSNER CLINIC FOUNDATION   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g MAINE MEDICAL CENTER   (United States)

^h Cardiovascular Medicine Davenport   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

more..

Author keywords

Coronary artery disease; Coronary stenosis; Drug eluting stent; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RAPAMYCIN; THROMBIN INHIBITOR; TICLOPIDINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; FEMALE; HUMAN; IMPLANT; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; REVASCULARIZATION; SAFETY; STENT THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; UNSTABLE ANGINA PECTORIS; VASCULAR LESION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 1; DRUG-ELUTING STENTS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OFF-LABEL USE; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SIROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 76749158901     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Lemos PA, Serruys PW, Van Domburg RT, et al. Unrestricted utilization of sirolimuseluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
4. Zahn R, Hamm CW, Zeymer U, et al. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry]. Herz 2004;29(2):181-186. (Pubitemid 38495892)
5. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
6. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
7. Shaw RE, Anderson HV, Brindis RG, et al. Updated risk adjustment mortality model using the complete 1.1 dataset from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). J Invasive Cardiol 2003;15:578-580.
8. Cohen HA, Williams DO, Holmes DR Jr, et al. Impact of age on procedural and 1- year outcome in percutaneous transluminal coronary angioplasty: A report from the NHLBI Dynamic Registry. Am Heart J 2003;146:513-519.
9. Al Suwaidi J, Yeh W, Cohen HA, et al. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001;87:1139-1144.
10. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.
11. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-1441.
12. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: Results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118:2277-2285, 7p following 2285.
13. Mulukutla SR, Vlachos HA, Marroquin OC, et al. Impact of drug-eluting stents among insulin-treated diabetic patients A report from the NHLBI Dynamic Registry. JACC Cardiovasc Interv 2008;1:139-147.
14. Price MJ, Teirstein PS. The off- versus on-label use of medical devices in interventional cardiovascular medicine: Clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI. Catheter Cardiovasc Interv 2008;72:500-504.
15. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000.